ArticleVaccines2022
An Optimal Control Model to Understand the Potential Impact of the New Vaccine and Transmission-Blocking Drugs for Malaria: A Case Study in Papua and West Papua, Indonesia.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 25 citations in OpenAlex.
- Forecasting and quantifying the role of vaccination strategies in the 2025 Texas measles outbreak: a modeling and time series analysis approach.BMC infectious diseases · 2026Article
- Optimal control and cost-effectiveness analysis of PfSPZ vaccination and indoor residual spraying in malaria transmission: a case study in Keerom.Frontiers in public health · 2026Article
- Age-structured vaccination strategies in mathematical modeling of malaria transmission.Current research in parasitology & vector-borne diseases · 2025Article
- Improving tuberculosis control: assessing the value of medical masks and case detection-a multi-country study with cost-effectiveness analysis.Royal Society open science · 2024Article
- Optimal control of a two-group malaria transmission model with vaccination.Network modeling and analysis in health informatics and bioinformatics · 2023Article
- Assessing the Impact of Relapse, Reinfection and Recrudescence on Malaria Eradication Policy: A Bifurcation and Optimal Control Analysis.Tropical medicine and infectious disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Malaria is one of the major causes of a high death rate due to infectious diseases every year. Despite attempts to eradicate the disease, results have not been very successful. New vaccines and other treatments are being constantly developed to seek optimal ways to prevent malaria outbreaks. In this article, we formulate and analyze an optimal control model of malaria incorporating the new pre-erythrocytic vaccine and transmission-blocking treatment. Sufficient conditions to guarantee local stability of the malaria-free equilibrium were derived based on the controlled reproduction number condition. Using the non-linear least square fitting method, we fitted the incidence data from the province of Papua and West Papua in Indonesia to estimate the model parameter values. The optimal control characterization and optimality conditions were derived by applying the Pontryagin Maximum Principle, and numerical simulations were also presented. Simulation results show that both the pre-erythrocytic vaccine and transmission-blocking treatment significantly reduce the spread of malaria. Accordingly, a high doses of pre-erythrocytic vaccine is needed if the number of infected individuals is relatively small, while transmission blocking is required if the number of infected individuals is relatively large. These results suggest that a large-scale implementation of both strategies is vital as the world continues with the effort to eradicate malaria, especially in endemic regions across the globe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.